Optimal timing of post-treatment [18F]fluorodeoxyglucose-PET/CT for patients with head and neck malignancy

Nuclear Medicine Communications

Volumn 34, Issue 2, 2013, Pages 162-167

  Nakamura, Shin ^a   Toriihara, Akira ^a   Okochi, Kiyoshi ^a   Watanabe, Hiroshi ^a   Shibuya, Hitoshi ^a   Kurabayashi, Tohru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

18F FDG PET CT; head and neck; optimal timing; post treatment

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SURVEILLANCE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT NEURILEMOMA; MELANOMA; MYOEPITHERIAL CARCINOMA; SALIVARY GLAND DUCT CARCINOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84871611113     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835bdfe3     Document Type: Article

References (19)

1. Lell M, Baum U, Greess H, Nomayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol 2000; 33:239-247.
2. Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D,Wieser S, Heinisch M, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001; 28:816-821.
3. Laubenbacher C, Saumweber D,Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36:1747-1757.
4. Fischbein NJ, AAssar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, et al. Clinical utility of positron emission tomography with 18Ffluorodeoxyglucose in detecting residual/recurrent squamous cell cercinoma of the head and neck. Am J Neuroradiol 1998; 19:1189-1196.
5. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20:4199-4208.
6. Kunkel M, Forster GJ, Reichert TE, Jeong JH, Benz P, Bartenstein P, et al. Detection of recurrent oral squamous cell carcinoma by [18F]-2- fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer 2003; 98:2257-2265.
7. Ryan WR, Fee WE, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115:645-650.
8. Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18:651-658.
9. Kitagawa Y, Nishizawa S, Sano K, Ogasawara T, Nakamura M, Sadato N, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003; 44:198-206.
10. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dualhead position emission tomography. Eur J Nucl Med 1999; 26:767-773.
11. Terhaard CH, Bongers V, von Rijk PP, Hordijk GJ. F-18-fluoro-deoxy- glucose positron-emission tomography scanning of local laryngeal/pharyngeal cancer. Head Neck 2001; 23:933-941.
12. Murata Y, Watanabe H, Kubota K, Toda K, Nakamura S, Okouchi K, et al. PET/CT evaluation of the physiologic accumulation of 18F-FDG within the gallbladder vesicle. Nucl Med Biol 2007; 34:961-966.
13. Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007; 85:327-335.
14. Ng SH, Yen TC, Chang JTC, Chan SC, Ko SF,Wang HM, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006; 24:4371-4376.
15. Salaun PY, Abgral R, Querellou S, Couturier O, Valette G, Bizais Y, et al. Does 18-fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck 2007; 29:1115-1120.
16. Perie S, Hugentobler A, Susini B, Balogova S, Grahek D, Kerrou K, et al. Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2007; 137:647-653.
17. Greven KM,Williams DW, Keyes JW, McGuirt WF,Watson NE, Randall ME, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74:1355-1359.
18. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110:1493-1497.
19. Lee JC, Kim JS, Lee JH, Nam SY, Choi SH, Lee SW, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol 2007; 43:686-692.